PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32510630-5 2021 The 2bF9/MGMT-transduced cells were effectively enriched after drug selection by O6 -benzylguanine/1,3-bis-2-chloroethyl-1-nitrosourea. Carmustine 99-134 O-6-methylguanine-DNA methyltransferase Mus musculus 9-13 15308322-5 2004 Optimum selection ex vivo of GFP-MGMT*-transduced HSC occurred with BG (2.5-10 microM)/BCNU (5-10 microM) or TMZ (100-200 microM), which increases marking while preserving maximum viable transduced cells. Carmustine 87-91 O-6-methylguanine-DNA methyltransferase Mus musculus 33-37 19844954-2 2010 We increased the frequency of O6-ChlEt-G lesions by pretreatment with an inhibitor of O(6)-methylguanine-DNA methyltransferase (MGMT), O(6)-benzylguanine (O6BG), and subsequent treatment with bis-chloroethylnitrosourea (BCNU). Carmustine 192-218 O-6-methylguanine-DNA methyltransferase Mus musculus 128-132 19844954-2 2010 We increased the frequency of O6-ChlEt-G lesions by pretreatment with an inhibitor of O(6)-methylguanine-DNA methyltransferase (MGMT), O(6)-benzylguanine (O6BG), and subsequent treatment with bis-chloroethylnitrosourea (BCNU). Carmustine 220-224 O-6-methylguanine-DNA methyltransferase Mus musculus 86-126 19844954-2 2010 We increased the frequency of O6-ChlEt-G lesions by pretreatment with an inhibitor of O(6)-methylguanine-DNA methyltransferase (MGMT), O(6)-benzylguanine (O6BG), and subsequent treatment with bis-chloroethylnitrosourea (BCNU). Carmustine 220-224 O-6-methylguanine-DNA methyltransferase Mus musculus 128-132 17116724-2 2007 Using Mgmt-/- mice, we examined MGMT"s role in protecting from in vivo mutations induced by three different alkylating agents, temozolomide (TMZ), 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) and cyclophosphamide. Carmustine 147-184 O-6-methylguanine-DNA methyltransferase Mus musculus 32-36 17116724-2 2007 Using Mgmt-/- mice, we examined MGMT"s role in protecting from in vivo mutations induced by three different alkylating agents, temozolomide (TMZ), 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) and cyclophosphamide. Carmustine 186-190 O-6-methylguanine-DNA methyltransferase Mus musculus 32-36 18076130-5 2008 RESULTS: We found that multiple cycles of O(6)-benzylguanine (BG)/1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) treatment at a dosage effective for ex vivo HSC selection led to a two-fold increase of MGMT-expressing primary hepatocytes under culture conditions with minimum cell expansion. Carmustine 66-102 O-6-methylguanine-DNA methyltransferase Mus musculus 198-202 18076130-5 2008 RESULTS: We found that multiple cycles of O(6)-benzylguanine (BG)/1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) treatment at a dosage effective for ex vivo HSC selection led to a two-fold increase of MGMT-expressing primary hepatocytes under culture conditions with minimum cell expansion. Carmustine 104-108 O-6-methylguanine-DNA methyltransferase Mus musculus 198-202 16927363-6 2006 RESULTS: Expression of the transgene provided chemoprotection and allowed in vivo selection of MGMT(P140K)-expressing cells in transgenic mice after exposure to O6-benzylguanine (BG) and N,N"-bis(2-chloroethyl)-N-nitrosourea (BCNU). Carmustine 187-224 O-6-methylguanine-DNA methyltransferase Mus musculus 95-99 16927363-6 2006 RESULTS: Expression of the transgene provided chemoprotection and allowed in vivo selection of MGMT(P140K)-expressing cells in transgenic mice after exposure to O6-benzylguanine (BG) and N,N"-bis(2-chloroethyl)-N-nitrosourea (BCNU). Carmustine 226-230 O-6-methylguanine-DNA methyltransferase Mus musculus 95-99 16390267-5 2005 To date, the best results have been observed with O(6)-methylguanine-DNA methyltransferase (MGMT) selection, with which increases in gene-marked repopulating cells have been maintained long-term, likely because of the toxicity of 1,3-bis-(2-chloroethyl)-1-nitrosourea and temozolomide to quiescent HSCs. Carmustine 230-267 O-6-methylguanine-DNA methyltransferase Mus musculus 50-90 16390267-5 2005 To date, the best results have been observed with O(6)-methylguanine-DNA methyltransferase (MGMT) selection, with which increases in gene-marked repopulating cells have been maintained long-term, likely because of the toxicity of 1,3-bis-(2-chloroethyl)-1-nitrosourea and temozolomide to quiescent HSCs. Carmustine 230-267 O-6-methylguanine-DNA methyltransferase Mus musculus 92-96 15284838-4 2004 We used bicistronic SIN-lentiviral vectors coexpressing EGFP or FECH and the G156A-mutated O6-methylguanine-DNA-methyltransferase (MGMT) gene, which allowed efficient in vivo selection of transduced HSCs after O6-benzylguanine and BCNU treatment. Carmustine 231-235 O-6-methylguanine-DNA methyltransferase Mus musculus 131-135 14506174-0 2003 Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2"-deoxyguanosine. Carmustine 48-58 O-6-methylguanine-DNA methyltransferase Mus musculus 101-139 14707273-1 2003 The major mechanism of tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) is the DNA repair protein O(6)-methylguanine DNA methyltransferase (MGMT). Carmustine 48-84 O-6-methylguanine-DNA methyltransferase Mus musculus 160-164 14707273-1 2003 The major mechanism of tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) is the DNA repair protein O(6)-methylguanine DNA methyltransferase (MGMT). Carmustine 86-90 O-6-methylguanine-DNA methyltransferase Mus musculus 160-164 14707273-4 2003 We have shown previously that retroviral expression of the P140K mutant of MGMT (MGMT-P140K) in murine and human hematopoietic cells produces significant resistance of bone marrow cells to low-dose, combination BG and BCNU treatment in vivo. Carmustine 218-222 O-6-methylguanine-DNA methyltransferase Mus musculus 75-79 14707273-4 2003 We have shown previously that retroviral expression of the P140K mutant of MGMT (MGMT-P140K) in murine and human hematopoietic cells produces significant resistance of bone marrow cells to low-dose, combination BG and BCNU treatment in vivo. Carmustine 218-222 O-6-methylguanine-DNA methyltransferase Mus musculus 81-86 14707273-5 2003 In the current study, we investigated the ability of bone marrow transplantation with MGMT-P140K-transduced hematopoietic cells to protect against an intensive antitumor treatment regimen of combination BG and BCNU in non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice. Carmustine 210-214 O-6-methylguanine-DNA methyltransferase Mus musculus 86-91 14707273-7 2003 Tolerance to the intensive BG and BCNU treatment was markedly improved in secondary MGMT-P140K-transplanted mice (n = 19) compared to untransplanted mice (n = 15), as indicated by blood counts and survival rate. Carmustine 34-38 O-6-methylguanine-DNA methyltransferase Mus musculus 84-89 14707273-8 2003 The dose-intensified BG and BCNU therapy produced significant growth delays of glioma xenografts in MGMT-P140K-transplanted mice, extending the tumor doubling time by >40 days. Carmustine 28-32 O-6-methylguanine-DNA methyltransferase Mus musculus 100-105 14506174-6 2003 Pretreatment with the MGMT inactivators BG or dBG reduced the maximum-tolerated doses of BCNU and TMZ to 35 and 170 mg/m(2), respectively. Carmustine 89-93 O-6-methylguanine-DNA methyltransferase Mus musculus 22-26 12965075-9 2003 These data indicate that strong selection pressure using the MGMT gene to protect primary and secondary repopulating murine stem cells from the toxicity of BCNU. Carmustine 156-160 O-6-methylguanine-DNA methyltransferase Mus musculus 61-65 11553261-6 2001 In comparison to mock-transduced controls, after transduction with N2/Zip-PGK-MGMT the IC50 for CFU increased on average 4.7-fold for ACNU, 2.5-fold for BCNU, 6.3-fold for CCNU and 1.5-fold for temozolomide. Carmustine 153-157 O-6-methylguanine-DNA methyltransferase Mus musculus 78-82 12439597-1 2002 PURPOSE: The DNA-repair protein, O6-alkylguanine-DNA alkyl transferase, may account for resistance of CNS tumors to DNA-alkylating drugs, such as bis-(2-chloroethyl)-1-nitrosourea (BCNU). Carmustine 146-179 O-6-methylguanine-DNA methyltransferase Mus musculus 33-70 12439597-1 2002 PURPOSE: The DNA-repair protein, O6-alkylguanine-DNA alkyl transferase, may account for resistance of CNS tumors to DNA-alkylating drugs, such as bis-(2-chloroethyl)-1-nitrosourea (BCNU). Carmustine 181-185 O-6-methylguanine-DNA methyltransferase Mus musculus 33-70 9816307-2 1996 We have shown that high-efficiency myeloproliferative sarcoma virus (vM5MGMT)-mediated transduction of the human MGMT cDNA into murine bone marrow (BM) cells leads to high MGMT expression and increased progenitor resistance to 1,3-bis-(2-chloroethyl) nitrosourea (BCNU) in vitro immediately after infection and after BM transplantation. Carmustine 227-262 O-6-methylguanine-DNA methyltransferase Mus musculus 113-117 10807772-2 2000 We selected for G156A MGMT (triangle upMGMT) transduced LTRC present in 5 x 10(4) to 100 x 10(4) marrow cells infused into nonmyeloablated mice by the administration of O(6)-benzylguanine (BG) and BCNU every 3 to 4 weeks. Carmustine 197-201 O-6-methylguanine-DNA methyltransferase Mus musculus 22-26 10188873-2 1999 This study examined the effect of O6-alkylguanine-DNA-alkyltransferase (ATase) depletion by the pseudosubstrate O6-benzylguanine (BG) on the anti-tumour activity and normal tissue toxicity in mice of three such molecular combinations, in comparison with BCNU. Carmustine 254-258 O-6-methylguanine-DNA methyltransferase Mus musculus 72-77 9371508-7 1997 The degree of drug resistance in deltaMGMT-transduced hematopoietic progenitors to BG and BCNU was much greater than we observed previously with wild-type MGMT gene transfer and treatment with BCNU alone. Carmustine 90-94 O-6-methylguanine-DNA methyltransferase Mus musculus 38-42 9293904-2 1997 In the present study we show that MGMT expressing bone marrow (BM) progenitors can be selected for in vivo by BCNU administration. Carmustine 110-114 O-6-methylguanine-DNA methyltransferase Mus musculus 34-38 9293904-3 1997 MGMT+ mice treated with multiple doses of BCNU and examined 13 to 17 weeks after transplantation displayed a 2.4-fold increase in the percentage of progenitors with evidence of proviral integration (p < 0.0001). Carmustine 42-46 O-6-methylguanine-DNA methyltransferase Mus musculus 0-4 10647505-2 2000 PURPOSE: O6-Benzylguanine (BG), an O6-methylguanine-DNA methyltransferase (MGMT) inactivator, potentiates the efficacy of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and of other DNA chloroethylating and methylating anticancer drugs and is currently undergoing clinical trials. Carmustine 122-158 O-6-methylguanine-DNA methyltransferase Mus musculus 35-73 10647505-2 2000 PURPOSE: O6-Benzylguanine (BG), an O6-methylguanine-DNA methyltransferase (MGMT) inactivator, potentiates the efficacy of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and of other DNA chloroethylating and methylating anticancer drugs and is currently undergoing clinical trials. Carmustine 122-158 O-6-methylguanine-DNA methyltransferase Mus musculus 75-79 10647505-2 2000 PURPOSE: O6-Benzylguanine (BG), an O6-methylguanine-DNA methyltransferase (MGMT) inactivator, potentiates the efficacy of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and of other DNA chloroethylating and methylating anticancer drugs and is currently undergoing clinical trials. Carmustine 160-164 O-6-methylguanine-DNA methyltransferase Mus musculus 75-79 10375003-3 1999 Primary mouse embryo fibroblasts and bone marrow cells from Mgmt -/- mice were significantly more sensitive to the toxic effects of the chemotherapeutic alkylating agents 1,3-bis(2-chloroethyl)-1-nitrosourea, streptozotocin and temozolomide than those from Mgmt wild-type mice. Carmustine 171-207 O-6-methylguanine-DNA methyltransferase Mus musculus 60-64 8993023-0 1997 Reversal of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced severe immunodeficiency by transduction of murine long-lived hemopoietic progenitor cells using O6-methylguanine DNA methyltransferase complementary DNA. Carmustine 12-48 O-6-methylguanine-DNA methyltransferase Mus musculus 153-191 8993023-6 1997 Mice transplanted with either mock-infected control or PGK-MGMT-transduced stem cells were treated with five weekly doses of BCNU. Carmustine 125-129 O-6-methylguanine-DNA methyltransferase Mus musculus 59-63 8993023-8 1997 In contrast, the profound deficiency in CD4+CD8+ double-positive thymocytes and mature lymphocytes observed in control mice surviving BCNU treatment was completely reversed in mice transplanted with PGK-MGMT-transduced bone marrow and was associated with molecular evidence of in vivo selection of transduced cells in the lymphoid compartment. Carmustine 134-138 O-6-methylguanine-DNA methyltransferase Mus musculus 203-207 9816307-2 1996 We have shown that high-efficiency myeloproliferative sarcoma virus (vM5MGMT)-mediated transduction of the human MGMT cDNA into murine bone marrow (BM) cells leads to high MGMT expression and increased progenitor resistance to 1,3-bis-(2-chloroethyl) nitrosourea (BCNU) in vitro immediately after infection and after BM transplantation. Carmustine 264-268 O-6-methylguanine-DNA methyltransferase Mus musculus 113-117 8552605-4 1996 Stable reconstitution of mouse bone marrow with genetically modified, MGMT-expressing hematopoietic stem cells conferred considerable resistance to the cytotoxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), a CNU commonly used for chemotherapy. Carmustine 173-209 O-6-methylguanine-DNA methyltransferase Mus musculus 70-74 8552605-4 1996 Stable reconstitution of mouse bone marrow with genetically modified, MGMT-expressing hematopoietic stem cells conferred considerable resistance to the cytotoxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), a CNU commonly used for chemotherapy. Carmustine 211-215 O-6-methylguanine-DNA methyltransferase Mus musculus 70-74 8552605-6 1996 Moreover, MGMT expression in mouse bone marrow conferred in vivo resistance to BCNU-induced pancytopenia and significantly reduced BCNU-induced mortality due to bone marrow hypoplasia. Carmustine 79-83 O-6-methylguanine-DNA methyltransferase Mus musculus 10-14 8552605-6 1996 Moreover, MGMT expression in mouse bone marrow conferred in vivo resistance to BCNU-induced pancytopenia and significantly reduced BCNU-induced mortality due to bone marrow hypoplasia. Carmustine 131-135 O-6-methylguanine-DNA methyltransferase Mus musculus 10-14 7780976-5 1995 Infection of murine bone marrow with the N2/ZipPGK-MGMT retrovirus significantly increased the survival of murine bone marrow-committed progenitor cells following in vitro exposure to N-N"-bis(2-chloroethyl)-N-nitrosourea (BCNU, carmustine). Carmustine 184-221 O-6-methylguanine-DNA methyltransferase Mus musculus 51-55 7780976-5 1995 Infection of murine bone marrow with the N2/ZipPGK-MGMT retrovirus significantly increased the survival of murine bone marrow-committed progenitor cells following in vitro exposure to N-N"-bis(2-chloroethyl)-N-nitrosourea (BCNU, carmustine). Carmustine 223-227 O-6-methylguanine-DNA methyltransferase Mus musculus 51-55 7780976-5 1995 Infection of murine bone marrow with the N2/ZipPGK-MGMT retrovirus significantly increased the survival of murine bone marrow-committed progenitor cells following in vitro exposure to N-N"-bis(2-chloroethyl)-N-nitrosourea (BCNU, carmustine). Carmustine 229-239 O-6-methylguanine-DNA methyltransferase Mus musculus 51-55 7780976-6 1995 MGMT gene transfer also protected murine hematopoietic cells in vivo in a murine model of BCNU-induced myelosuppression. Carmustine 90-94 O-6-methylguanine-DNA methyltransferase Mus musculus 0-4 7923129-1 1994 O6-Benzylguanine effectively inactivates the DNA repair protein, O6-alkylguanine-DNA alkyltransferase, leading to an increase in the therapeutic index of 1,3-bis(2-chloroethyl)-1-nitrosourea in nude mouse xenograft studies. Carmustine 154-190 O-6-methylguanine-DNA methyltransferase Mus musculus 65-101 1537073-2 1992 At the population level, we found that BCNU-resistant cells (L1210/BCNU) that appeared to be cross-resistant to killing by a dimethyltriazene and expressed high levels of O6-methylguanine-DNA methyltransferase activity (mer+ phenotype) failed to generate highly immunogenic variant sublines on repeated exposure to the methylating agents. Carmustine 39-43 O-6-methylguanine-DNA methyltransferase Mus musculus 171-209